NCT01734850View on ClinicalTrials.gov

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Busulfan

Intravenous busulfan

BIOLOGICAL

Cal-1 modified HSPC

Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)

BIOLOGICAL

Cal-1 modified CD4+ T lymphocytes

CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)

Trial Locations (2)

90035

UCLA CARE Center, Los Angeles

94115

Quest Clinical Research, San Francisco

Sponsors

Lead Sponsor

Calimmune, Inc.
All Listed Sponsors
lead

Calimmune, Inc.

INDUSTRY